

CORRECTION


Correction: Evaluating the pentapharmacological potency of otamixaban against lung cancer CDK2, transferase, oxidoreductase and signalling proteins

Hanadi M. Baeissa, Tahani Bakhsh, Afnan Mohammed Shakoori, Ghadir Sindi, Randa Mohammed Zaki, Mohammad Azhar Kamal, Hadeel A. Alsufyani, Alaa Hamed Habib, Arwa Ishaq A. Khayyat, Misbahuddin Rafeeq, Deeba Shamim Jairajpuri

The Funding statement for this article is incorrect. The correct Funding statement is as follows: This study is supported by Prince Sattam bin Abdulaziz University, project number PSAU/2024/R/1445

Reference

1. Baeissa HM, Bakhsh T, Shakoori AM, Sindi G, Zaki RM, Kamal MA, et al. Evaluating the pentapharmacological potency of otamixaban against lung cancer CDK2, transferase, oxidoreductase and signalling proteins. PLoS One. 2025;20(10):e0334013. <https://doi.org/10.1371/journal.pone.0334013> PMID: [41066396](https://pubmed.ncbi.nlm.nih.gov/41066396/)



OPEN ACCESS

Citation: Baeissa HM, Bakhsh T, Shakoori AM, Sindi G, Zaki RM, Kamal MA, et al.

(2026) Correction: Evaluating the pentapharmacological potency of otamixaban against lung cancer CDK2, transferase, oxidoreductase and signalling proteins. PLoS One 21(3): e0344592. <https://doi.org/10.1371/journal.pone.0344592>

Published: March 9, 2026

Copyright: © 2026 Baeissa et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.